Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

A Georgia woman who lost 60 pounds taking semaglutide spent nearly $20,000 on a 'mommy makeover' only to pile the weight back ...

The former Big Brother contestant turned to the controversial weight loss jab after gaining two stone in weight following the ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

GetSimpli Oral Semaglutide offers a promising solution ... issues should discuss their health status with their doctor before starting the product. Overall, while side effects can occur, the ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

The dose of semaglutide was gradually increased up to 1 mg or the maximum tolerated dose. During the last 4 weeks of the 15, participants used a research-created automated insulin pump. After this ...

You might experience: Before stopping semaglutide ... Getting back to normal after stopping semaglutide may feel daunting, but with the right approach, it’s entirely achievable.

If you’ve recently stopped taking semaglutide—commonly known by brand ... There's already speculation he might veto it, after he continued to strike down the legislation calling it "weak." ...